India to Thailand: Acarbose Export Trade Route

To import finished pharmaceutical products into Thailand, the following steps must be undertaken:

1. Drug Facility Licensing: Importers must obtain a license from the Thai FDA. Applications are submitted to the FDA for facilities in Bangkok or to the Provincial Public Health Office for facilities in other provinces. (en.fda.moph.go.th)

2. Product Registration: Each pharmaceutical product, including Acarbose formulations, must be registered with the Thai FDA before importation. The registration dossier should follow the ASEAN Common Technical Dossier (ACTD) or the International Council for Harmonisation's Common Technical Document (ICH CTD) format. (en.fda.moph.go.th)

3. Approval Timelines and Fees: The approval process duration varies based on the product type and completeness of the application. Specific timelines and registration fees are determined by the Thai FDA and may differ accordingly.

4. GMP Inspection Requirements: Overseas manufacturing facilities producing Acarbose formulations must obtain GMP clearance from the Thai FDA, ensuring compliance with Good Manufacturing Practice standards. (en.fda.moph.go.th)

Indian exporters of Acarbose formulations must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturing facilities must comply with internationally recognized GMP standards. The Thai FDA requires GMP clearance for overseas facilities, confirming adherence to these standards. (en.fda.moph.go.th)

2. Approved Facilities: Specific information regarding Indian facilities currently approved by the Thai FDA is not publicly disclosed. Exporters should consult the Thai FDA for the most current list of approved manufacturers.

3. Regulatory Actions: As of March 2026, there have been no publicly reported regulatory actions by the Thai FDA against Indian pharmaceutical companies concerning Acarbose formulations.

Recent developments affecting pharmaceutical imports into Thailand include:

1. Elevated Manufacturing Standards: Effective November 1, 2024, the Thai FDA mandated that public hospitals producing medicines comply with the "PIC/S Guide to Good Practices for The Preparation of Medicinal Products in Healthcare Establishments," aligning hospital production standards with international norms. (en.fda.moph.go.th)

2. Medical Device Quality Systems: In April 2024, the Thai FDA issued notifications on Good Manufacturing Practice and Good Importing and Sales Practice for medical devices, effective July 2024. While these regulations pertain to medical devices, they reflect the Thai FDA's commitment to stringent quality systems across healthcare products.

These developments underscore Thailand's ongoing efforts to enhance pharmaceutical quality standards and regulatory compliance, impacting the importation and manufacturing of pharmaceutical products, including Acarbose formulations.

In 2025, the global market for oral Acarbose preparations was valued at approximately $800 million USD, with projections indicating growth to $856 million USD in 2026. While specific data for Thailand is not readily available, the country's increasing prevalence of type 2 diabetes, driven by an aging population and rising obesity rates, suggests a growing demand for Acarbose formulations. Thailand's universal health coverage and expanding healthcare infrastructure further support this demand. The balance between domestic manufacturing and imports of Acarbose formulations remains unclear, necessitating further investigation to determine the extent of local production versus reliance on imports.

Under HS code 30049099, Thailand imposes an MFN import duty rate of 30% on pharmaceutical products. Additionally, a Value Added Tax (VAT) is applied to imported goods. Thailand's participation in various FTAs may provide reduced tariff rates or exemptions for pharmaceutical imports from partner countries, contingent upon specific agreement terms. There are no publicly available records indicating the imposition of anti-dumping duties on Acarbose formulations imported into Thailand.

The primary suppliers of Acarbose formulations to Thailand include countries with robust pharmaceutical industries, such as China and European Union member states. India's contribution to Thailand's total Acarbose imports is currently minimal, with only one recorded shipment. Pricing dynamics are influenced by factors including production costs, regulatory compliance, and market demand. Indian pharmaceutical manufacturers are known for competitive pricing, which may offer cost advantages over counterparts from China and the EU. However, the limited volume of Indian exports to Thailand suggests that other factors, such as regulatory approvals and established supplier relationships, play significant roles in the competitive landscape.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Acarbose, such as tablets and capsules. The country's cost-effective production is attributed to economies of scale, competitive labor costs, and a well-established supply chain. In the fiscal year 2024, India registered 134 finished dosage form (FDF) manufacturing facilities with the U.S. FDA, underscoring its commitment to quality and regulatory compliance. Additionally, numerous Indian facilities hold WHO-GMP certifications, ensuring adherence to international manufacturing standards.

When comparing Acarbose formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers offer competitive pricing for Acarbose tablets. For instance, in November 2016, Acarbose 50mg tablets were exported from India at a unit price of approximately $0.09 per tablet. While more recent data is limited, India's cost advantages are well-documented.

• Quality Perception: Indian pharmaceutical companies are recognized for their adherence to international quality standards, with many facilities holding WHO-GMP and U.S. FDA approvals. This positions Indian Acarbose formulations favorably in terms of quality perception.

• Regulatory Acceptance in Thailand: Thailand's Food and Drug Administration (Thai FDA) recognizes WHO-GMP certifications, facilitating the registration and importation of Indian pharmaceutical products.

• Supply Reliability Track Record: Indian manufacturers have a strong track record of supplying pharmaceuticals globally, including to Thailand. The presence of multiple WHO-GMP certified facilities ensures consistent production and supply.

India's pharmaceutical industry boasts substantial manufacturing capacity for finished dosage forms, including Acarbose tablets. The country's infrastructure supports large-scale production, with facilities equipped for efficient packaging and distribution. As of November 2024, India registered 134 FDF manufacturing facilities with the U.S. FDA, reflecting its robust production capabilities. There have been no significant supply disruptions reported in recent years, indicating a reliable supply chain. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and U.S. FDA certifications. While specific data on capacity constraints or expansion plans for Acarbose formulations is limited, the overall industry trend suggests ongoing growth and investment in manufacturing capabilities.

For Thai buyers seeking to source Acarbose formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acarbose formulations.

• Minimum Order Quantities (MOQs): Indian pharmaceutical manufacturers typically require MOQs to optimize production efficiency. It's advisable to negotiate MOQs that align with your demand forecasts to balance cost-effectiveness and inventory management.

• Payment Terms: Common payment terms in India-Thailand pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Establish clear payment terms to ensure smooth financial transactions.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of WHO-GMP certifications, and assessment of regulatory compliance history.

• Regulatory Compliance: Ensure that the selected Indian manufacturers have a proven track record of compliance with international regulatory standards, facilitating smoother product registration and importation processes in Thailand.

By implementing these strategies, Thai buyers can establish a reliable and cost-effective supply chain for Acarbose formulations from India.

By meticulously following these guidelines, Thai companies can establish reliable and compliant partnerships with Indian manufacturers for Acarbose formulations, ensuring product quality and regulatory adherence.